Alector (ALEC) Sees Strong Trading Volume

Share on StockTwits

Shares of Alector Inc (NASDAQ:ALEC) saw unusually-strong trading volume on Friday . Approximately 1,554,491 shares were traded during mid-day trading, an increase of 231% from the previous session’s volume of 470,256 shares.The stock last traded at $18.05 and had previously closed at $17.35.

Several research analysts recently weighed in on ALEC shares. Svb Leerink started coverage on shares of Alector in a research report on Monday, March 4th. They issued an “outperform” rating on the stock. Bank of America began coverage on shares of Alector in a research report on Monday, March 4th. They set a “buy” rating and a $26.00 price target on the stock. Barclays began coverage on shares of Alector in a research report on Monday, March 4th. They set an “overweight” rating and a $27.00 price target on the stock. Leerink Swann began coverage on shares of Alector in a research report on Monday, March 4th. They set an “outperform” rating on the stock. Finally, Cowen began coverage on shares of Alector in a research report on Monday, March 4th. They set an “outperform” rating on the stock. Six research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and an average target price of $26.67.

In other Alector news, Director Orbimed Advisors Llc purchased 411,700 shares of Alector stock in a transaction on Monday, February 11th. The shares were acquired at an average cost of $19.00 per share, for a total transaction of $7,822,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

TRADEMARK VIOLATION NOTICE: “Alector (ALEC) Sees Strong Trading Volume” was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4224564/alector-alec-sees-strong-trading-volume.html.

Alector Company Profile (NASDAQ:ALEC)

Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.

See Also: Asset Allocation and Your Retirement

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Brokerages Set Scorpio Bulkers Inc  Price Target at $9.33
Brokerages Set Scorpio Bulkers Inc Price Target at $9.33
Argus Downgrades Expedia Group  to Hold
Argus Downgrades Expedia Group to Hold
Steelcase  Upgraded to Hold at Zacks Investment Research
Steelcase Upgraded to Hold at Zacks Investment Research
Freestone Capital Holdings LLC Has $835,000 Position in iShares Russell Mid-Cap Growth ETF
Freestone Capital Holdings LLC Has $835,000 Position in iShares Russell Mid-Cap Growth ETF
City Office REIT Inc  Shares Bought by Connor Clark & Lunn Investment Management Ltd.
City Office REIT Inc Shares Bought by Connor Clark & Lunn Investment Management Ltd.
Fiduciary Group LLC Acquires 378 Shares of Colgate-Palmolive
Fiduciary Group LLC Acquires 378 Shares of Colgate-Palmolive


© 2006-2019 Ticker Report